ADMA · Adma Biologics, Inc. · Insider Trading

Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon the non-reportable vesting and settlement of restricted stock units ("RSUs"). This is not an open market sale of securities.

Includes, as of the transaction date, (i) 91,631 unvested RSUs out of 91,631 RSUs granted on February 9, 2026, vesting 25% on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 58,338 unvested RSUs out of 77,784 RSUs granted on February 19, 2025, vesting 25% on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 96,160 unvested RSUs out of 192,320 RSUs granted on April 1, 2024, vesting 25% on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

(continued from footnote 2) (iv) 7,500 unvested RSUs out of 30,000 RSUs granted on July 24, 2023, vesting 25% on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (v) 23,750 unvested RSUs out of 95,000 RSUs granted on March 6, 2023, vesting 25% on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (vi) 165,682 shares of common stock directly owned by the Reporting Person, which reflects prior option exercises and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

This option was granted to the Reporting Person on July 16, 2026, and will vest over four years, with 25% of the shares subject to the option vesting on the one-year anniversary of the date of grant, and the remaining 75% of the shares subject to the option vesting over the subsequent three-year period in substantially equal monthly installments at a rate of 1/48th of the total shares subject to the option each month, becoming fully vested on July 16, 2030 in accordance with the Plan, subject to the Reporting Person's continued service as of the applicable vesting date.

These shares represent restricted stock units ("RSUs") that will vest quarterly on each annual anniversary of the date of grant over four years in accordance with the ADMA Biologics, Inc. 2022 Equity Compensation Plan (the "Plan"), subject to the Reporting Person's continued service as of the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

Includes, as of the transaction date, (i) 85,130 unvested RSUs granted on July 16, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (ii) 58,019 unvested RSUs granted on December 8, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

Represents an open market purchase in a single transaction.

Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, half of which will vest on August 9, 2026, and the other half of which will vest on February 9, 2027, subject to the Reporting Person's continued service as of each such vesting date; and (ii) 509,594 shares of common stock owned by the Reporting Person.

Represents an open market purchase in a single transaction.

Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, half of which will vest on August 9, 2026, and the other half of which will vest on February 9, 2027, subject to the Reporting Person's continued service as of each such vesting date; and (ii) 503,194 shares of common stock owned by the Reporting Person.

Represents an open market purchase in a single transaction.

Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; and (ii) 490,694 shares of common stock owned by the reporting person.

Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units ("RSUs"). This is not an open market sale of securities.

Includes, as of the transaction date (i) 91,631 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 58,338 unvested RSUs out of 77,784 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 96,160 unvested RSUs out of 192,320 RSUs granted on April 1, 2024, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date;

(continued from footnote 2) (iv) 15,000 unvested RSUs out of 30,000 RSUs granted on July 24, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date; (v) 23,750 unvested RSUs out of 95,000 RSUs granted on March 6, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date; and (vi) 161,359 shares of common stock directly owned by the Reporting Person, which reflects prior option exercises and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

This transaction involved the Reporting Person's gift of 30,000 shares of Issuer common stock to the Lawrence P Guiheen Irrevocable Trust DTD 9/20/19, Arlene Guiheen TTEE, Katherine M Guiheen TTEE (the "2019 Guiheen Irrevocable Trust"), over which Mr. Guiheen retains control. The Reporting Person disclaims beneficial ownership of the securities held by the 2019 Guiheen Irrevocable Trust, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

Includes 30,000 shares of common stock held in the 2019 Guiheen Irrevocable Trust.

This transaction involved the Reporting Person's gift of 30,000 shares of Issuer common stock to the Lawrence P Guiheen Irrevocable Trust DTD 9/20/19, Arlene Guiheen TTEE, Katherine M Guiheen TTEE (the "2019 Guiheen Irrevocable Trust"), over which Mr. Guiheen retains control. The Reporting Person disclaims beneficial ownership of the securities held by the 2019 Guiheen Irrevocable Trust, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; and (ii) 94,830 shares of common stock owned by the Reporting Person.

Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025.

Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025.

The price reported in Column 4 is the price at which the shares were sold.

Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025.

The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028.

Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025.

The price reported in Column 4 is the price at which the shares were sold.

Includes, as of the transaction date, (i) 282,529 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 189,017 unvested RSUs out of 252,022 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

(continued from footnote 2) (iii) 278,864 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 143,424 unvested RSUs out of 573,695 RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

(continued from footnote 3) and (v) 1,218,943 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; and (ii) 94,830 shares of common stock owned by the Reporting Person.

The Reporting Person is exercising this option due, in part, to its near-term expiration date.

These options vested in twenty-four equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.

The shares were transferred by the reporting person in accordance with the terms of a court-approved divorce settlement agreement (the "Divorce Settlement").

The incentive stock options were granted to the Reporting Person on February 25, 2021, and are fully vested.

The incentive stock options were granted to the Reporting Person on February 14, 2017, and are fully vested.

The incentive stock options were granted to the Reporting Person on July 19, 2021, and are fully vested.

The securities were sold by the Reporting Person in accordance with the terms of the Divorce Settlement.

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.59 to $15.65, inclusive. The reporting person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Includes, as of the transaction date (i) 91,631 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 58,338 unvested RSUs out of 77,784 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 144,240 unvested RSUs out of 192,320 RSUs granted on April 1, 2024, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date;

(continued from footnote 5) (iv) 15,000 unvested RSUs out of 30,000 RSUs granted on July 24, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date; (v) 23,750 unvested RSUs out of 95,000 RSUs granted on March 6, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date; and (vi) 133,641 shares of common stock directly owned by the Reporting Person, which reflects prior option exercises and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

The incentive stock options were granted to the Reporting Person on June 5, 2019, and are fully vested.

The incentive stock options were granted to the Reporting Person on August 19, 2020, and are fully vested.

Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units ("RSUs"). This is not an open market sale of securities.

Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units ("RSUs"). This is not an open market sale of securities.

Includes, as of the transaction date, (i) 282,529 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 189,017 unvested RSUs out of 252,022 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

(continued from footnote 2) (iii) 278,864 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 143,424 unvested RSUs out of 573,695 RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

(continued from footnote 3) and (v) 1,224,943 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units ("RSUs"). This is not an open market sale of securities.

The reporting person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (4) to this Form 4.

The reported transaction reflects the open market purchase of shares of the Issuer's common stock. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.35 to $15.42, inclusive.

Includes (i) 2,031,730 shares owned by Aisling Capital II LP, which is a fund that was established in 2007 with a 10 year life ("Aisling Capital"), and (ii) 14,000 shares owned by Aisling Arcturus Partners, LP ("Aisling Arcturus" and, together with Aisling Capital, "Aisling"), of which 7,000 were purchased on March 5, 2026 and 7,000 were purchased on March 6, 2026. Mr. Elms is Aisling Capital's designee for nomination to the Board. As a Managing Member of Aisling Capital Partners, LLC ("Aisling Partners"), a control person of Aisling, and as a member of the investment committee of Aisling Capital Partners, LP ("Aisling GP"), Mr. Elms may be deemed to be the beneficial owner of shares of common stock owned of record by Aisling. Mr. Elms disclaims beneficial ownership of the Issuer's shares owned by Aisling and Aisling Partners' ownership of the Issuer's options, except to the extent of his pecuniary interest therein.

Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units ("RSUs"). This is not an open market sale of securities.

The reported transaction reflects the open market purchase of shares of ADMA Biologics, Inc. (the "Issuer") common stock. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.58 to $15.74, inclusive.

The reporting person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (4) to this Form 4.

Includes (i) 2,031,730 shares owned by Aisling Capital II LP, which is a fund that was established in 2007 with a 10 year life ("Aisling Capital"), and (ii) 14,000 shares owned by Aisling Arcturus Partners, LP ("Aisling Arcturus" and, together with Aisling Capital, "Aisling"), of which 7,000 were purchased on March 5, 2026 and 7,000 were purchased on March 6, 2026. Mr. Elms is Aisling Capital's designee for nomination to the Board. As a Managing Member of Aisling Capital Partners, LLC ("Aisling Partners"), a control person of Aisling, and as a member of the investment committee of Aisling Capital Partners, LP ("Aisling GP"), Mr. Elms may be deemed to be the beneficial owner of shares of common stock owned of record by Aisling. Mr. Elms disclaims beneficial ownership of the Issuer's shares owned by Aisling and Aisling Partners' ownership of the Issuer's options, except to the extent of his pecuniary interest therein.

Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units ("RSUs"). This is not an open market sale of securities.

Includes, as of the transaction date, (i) 282,529 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 189,017 unvested RSUs out of 252,022 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

(continued from footnote 2) (iii) 278,864 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 286,848 unvested RSUs out of 573,695 RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

(continued from footnote 3) (v) 75,000 unvested RSUs out of 300,000 RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (vi) 1,092,470 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units ("RSUs"). This is not an open market sale of securities.

Includes, as of the transaction date, (i) 46,671 unvested RSUs out of 62,227 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 54,300 unvested RSUs granted on July 24, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

(continued from footnote 2) (iii) 37,500 unvested RSUs granted by the Company on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

(continued from footnote 3) (iv) 50,000 unvested RSUs, granted by the Company on June 26, 2023, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (v) 44,469 shares acquired in open market purchases and pursuant to the vesting of RSUs after the withholding of shares to cover applicable taxes.

Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units ("RSUs"). This is not an open market sale of securities.

Includes, as of the transaction date (i) 91,631 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 58,338 unvested RSUs out of 77,784 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 144,240 unvested RSUs out of 192,320 RSUs granted on April 1, 2024, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date;

(continued from footnote 2) (iv) 15,000 unvested RSUs out of 30,000 RSUs granted on July 24, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date; (v) 47,500 unvested RSUs out of 95,000 RSUs granted on March 6, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date; (vi) 10,000 unvested RSUs out of 40,000 RSUs granted on March 7, 2022, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date;

(continued from footnote 3) and (vii) 205,451 shares of common stock directly owned by the Reporting Person, which reflects prior option exercises and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units ("RSUs"). This is not an open market sale of securities.

Includes, as of the transaction date, (i) 282,529 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 189,017 unvested RSUs out of 252,022 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

(continued from footnote 2) (iii) 418,296 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 286,848 unvested RSUs out of 573,695 RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

(continued from footnote 3) (v) 75,000 unvested RSUs out of 300,000 RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (vi) 1,007,896 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025.

Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025.

The price reported in Column 4 is the price at which the shares were sold.

Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025.

The price reported in Column 4 is the price at which the shares were sold.

Includes, as of the transaction date, (i) 282,529 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

(continued from footnote 3) (iii) 418,296 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 286,848 unvested RSUs out of 573,695 RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

(continued from footnote 4) (v) 75,000 unvested RSUs out of 300,000 RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (vi) 969,684 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025.

The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028.

These options vest in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.

The options vest over four years with 25% of the shares of common stock underlying the option vesting on the one-year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 9, 2030 in accordance with the Plan.

These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service as of the applicable vesting date.

Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; (ii) 5,445 RSUs out of 10,889 RSUs granted on February 19, 2025, which will vest fully on February 19, 2026, subject to the Reporting Person's continued service as of such vesting date; and (iii) 472,749 shares of common stock owned by the reporting person.

These options vest in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.

These shares represent restricted stock units ("RSUs") that will vest quarterly on each annual anniversary of the date of grant over four years in accordance with the ADMA Biologics, Inc. 2022 Equity Compensation Plan (the "Plan"), subject to the Reporting Person's continued service as of the applicable vesting date.

Includes, as of the transaction date, (i) 282,529 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

(continued from footnote 3) (iii) 418,296 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 286,848 unvested RSUs out of 573,695 RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

(continued from footnote 4) (v) 75,000 unvested RSUs out of 300,000 RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (vi) 975,684 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

The options vest over four years with 25% of the shares of common stock underlying the option vesting on the one-year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 9, 2030 in accordance with the Plan.

These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service as of the applicable vesting date.

Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; (ii) 5,445 RSUs out of 10,889 RSUs granted on February 19, 2025, which will vest fully on February 19, 2026, subject to the Reporting Person's continued service as of such vesting date; and (iii) 246,885 shares of common stock owned by the Reporting Person.

These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service as of the applicable vesting date.

Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; (ii) 5,445 RSUs out of 10,889 RSUs granted on February 19, 2025, which will vest fully on February 19, 2026, subject to the Reporting Person's continued service as of such vesting date; and (iii) 29,484 shares of common stock owned by the Reporting Person.

These options vest in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.